Pathway to Cures, the venture philanthropy fund of the National Bleeding Disorders Foundation (NBDF), presented their annual fund update at the NBDF Research Round Table in Washington, DC last month.

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

Green Bay Packers offensive coordinator Adam Stenavich spoke to the media on Wednesday about the strengths of the offense and the key playmakers headed into a road playoff matchup against the Chicago ...